KYTX: miv-cel nears approval for SPS, with strong safety, efficacy, and expansion into gMG and MS
Transformative cell therapy miv-cel is advancing toward regulatory approval for SPS, showing strong safety and efficacy, with plans to expand into gMG and MS. High demand and premium pricing are anticipated, supported by robust clinical and natural history data.Based on Kyverna Therapeutics, Inc…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.